1.690 to 6.852); doxorubicin/congestive heart failure (1.154 to 5.004); and carmustine/leukopenia (3.796 to 5.650) and thrombocytopenia (3.796 to 5.644). Furthermore, the percentage of AERS reports associated with outcomes of hospitalization increased as follows: melphalan causing leukemia (0% to 37%, pϽ0.001), chromosomal aberrations (0% to 15.55%, pϽ0.001), bone marrow suppression (4.0% to 40.9%, pϽ0.001), or hypersensitivity (30.77% to 50.0%, pϽ0.01). The mortality outcome increased only for melphalan/leukemia (8.9% to 54.8%, pϽ0.001). Life-threatening outcomes increased for melphalan/leukemia (0% to 17.7%, pϭ0.016), melphalan/chromosomal aberrations (0 to 8.7%, pϽ0.001), carmustine leukopenia (0 to 17.7%, pϭ0.016), and carmustine/thrombocytopenia (0-20.3%, Pϭ0.045).
OBJECTIVES:
Eribulin is a non-taxane microtubule dynamics inhibitor that has demonstrated improved overall survival in a phase III study relative to commonly used therapies in late-line metastatic breast cancer (MBC) . This budget impact model (BIM) was developed to help US payers make informed decisions regarding addition of eribulin for the management of MBC. METHODS: From the perspective of US commercial payers, an Excel-based BIM was constructed upon a hypothetical plan of 1 million members. 600 women are estimated to be newly diagnosed with breast cancer; of these 5% with MBC and 24% are initiated on 3 rd -line chemotherapy, 47% of these on monotherapy. A Markov decision-analytic model was used to trace movement of patients receiving eribulin or another 3 rd -line single-agent chemotherapies through different MBC states (treatment initialization, stable, response, progression, death). The model used a two-year time horizon with oneweek Markov cycle lengths. The efficacy, market shares, and medical and drug costs were derived using published and internally available data sources. Model probabilities were based on discontinuation, progression free survival, and overall survival rates from the EMBRACE trial. Market share of eribulin was assumed to be 5% in year-one and 10% in year-two of the model. Model outcomes included: total costs over 2 years pre-and post-inclusion of eribulin, net costs, cost per member per month (PMPM), cost per patient per month (PPPM) and median overall survival. RESULTS: Of the 1 million plan members, approximately 3 incident cases of MBC requiring 3rd line treatment were identified each year. Budgetary impact PMPM was estimated to be Ͻ$0.01 in year-one and year-two, and PPPM $118 and $252, respectively. Overall net budgetary impact for year-one and year-two was $4,880 and $10,450, respectively. CONCLUSIONS: Based on this analysis adding eribulin does not exhibit a significant overall cost increase when taking into account medical and drug expenditures.
PCN26 BUDGET IMPACT MODEL OF DENOSUMAB FOR SKELETAL RELATED EVENT (SRE) PREVENTION IN PATIENTS WITH BREAST AND PROSTATE CANCER
Northridge K 1 , Richhariya A 2 , Halperin M 1 , Chung K 2 , Danese MD 1 1 Outcomes Insights, Inc., Westlake Village, CA, USA, 2 Amgen, Inc., Thousand Oaks, CA, USA OBJECTIVES: Skeletal complications from bone metastases can be debilitating and costly. Denosumab was recently approved in the US for SRE prevention in patients with bone metastases from solid tumors. This study evaluated the three-year budget impact of denosumab compared to zoledronic acid (ZA) for breast and prostate cancer using the US managed care perspective. METHODS: Excel-based models compared denosumab (120 mg) to ZA (4 mg) administered every four weeks for the patient lifetime. Inputs included the US population age and gender distribution, Medicare managed care enrollment rates, the prevalence of bone metastases (estimated from literature-based epidemiological simulations), and 2010 costs for therapy and SREs. Utilization estimates assumed that 66% of breast and 48% of prostate cancer patients with bone metastases would receive anti-resorptive therapy and that for years one to three 20%, 35% and 45% of these patients would use denosumab. Trial-based SRE rates per patient-year were 0.488 and 0.631 (denosumab and ZA) for breast cancer and 0.746 and 0.947 for prostate cancer. The expected incremental adverse event cost was nominal and therefore excluded. Sensitivity analyses were conducted to identify influential variables on the incremental costs per member per month (PMPM). RESULTS: The incremental PMPM costs for years one to three were $0.02, $0.04, and $0.05 ($0.11 total) for breast cancer and $0.01, $0.02, and $0.03 ($0.06 total) for prostate cancer. For both tumor types, influential variables included costs for denosumab and ZA, prevalence rates of each cancer and of bone metastases, utilization rates of denosumab and ZA, and underlying SRE rates. The younger breast cancer age distribution results in a larger incremental cost burden for managed care organizations when compared to prostate cancer. CONCLUSIONS: The real-world financial impact to US health plans from using denosumab should be relatively modest and will vary depending on prevalence and utilization patterns. OBJECTIVES: Skeletal complications from bone metastases impose a significant clinical and economic burden on patients and health systems. Zoledronic acid (ZA) has been the mainstay for prevention of skeletal related events (SREs) in patients with bone metastases. In 2010, FDA approved denosumab for prevention of SREs in patients with solid-tumor bone metastases. We assessed the financial impact to a managed-care plan of adding denosumab to a ZA-only formulary for this indication. METHODS: We developed an Excel-based model to evaluate the trajectory of spending over 1-3 year time horizons in a hypothetical managed care plan with 1 million members and 688 patients with solid-tumor bone metastases. The model considered use and associated costs of drug acquisition and administration, SRE management, and adverse event (AE) treatment under two scenarios: (1) Base Case-ZA-only formulary; and (2) Restricted Formulary-denosumab limited to second-line treatment in patients failing ZA. SREs included pathologic fracture, therapeutic radiology, spinal cord compression, and orthopaedic surgery. AEs included osteonecrosis of the jaw, renal problems, acute phase reactions, and hypocalcemia. Model parameters were derived from published literature, product labels, clinical trial data, and administrative cost databases. Drug costs were based on published wholesale acquisition cost minus copayments. Costs were stated as 2010 US dollars. RESULTS: In the Base Case scenario (ZA only), total costs were $10.8 million per year. Allowing restricted access to denosumab was associated with total costs of $11.4, $11.6, and $11.7 million over 1, 2, and 3 years ($0.05, $0.06, $0.08 incrementally per-member per-month). The corresponding incremental cost of adding denosumab was $69, $94, and $115 per ZA-treated member per month. CONCLUSIONS: With an acquisition cost nearly twice that of ZA, restricted use of denosumab adds considerably to patient management costs. Incremental benefits should be weighed carefully against these costs before considering coverage. 
PCN27 COMPARATIVE BUDGET IMPACT OF FORMULARY INCLUSION OF ZOLEDRONIC ACID AND DENOSUMAB FOR PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES

PCN28 COST SAVINGS WITH FERRIC CARBOXYMALTOSE THROUGH ITS IMPACT ON ERYTHROPOÏESIS-STIMULATING AGENTS AND BLOOD TRANSFUSION IN CHEMOTHERAPY-INDUCED ANEMIA OF BREAST AND GASTROINTESTINAL CANCER: FRENCH HEALTH CARE PAYER PERSPECTIVE
OBJECTIVES:
To evaluate the economic impact of intravenous iron (ferric carboxymaltose; Ferinject) in chemotherapy-induced ferriprive anemia in breast and gastrointestinal cancer. METHODS: We used an economic model which compared the usual therapeutic strategies of anemia with or without intravenous iron. Costs related to anemia treatment by ESA, blood transfusion and intravenous iron were estimated and compared. Cost savings were calculated from the French healthcare payer perspective. Data included in the economic model were obtained from scientific literature, public health agencies and medical experts. Impact of Ferinject on the decrease of the number of blood transfusions at hospital and the decrease of ESA dosing was evaluated. RESULTS: Patients treated with 2000 mg of Ferinject during chemotherapy treatment and 1000 mg at home concomitantly with ESA once every two month during 4 months. Based on the estimated decreased of the 25% ESA dosing when administered with Ferinject, and a decrease of 10% of patients receiving ESA after chemotherapy (expert opinion), the most prominent annual cost savings were observed in chemotherapy-induced anemia in breast cancer (€881 and €319 by patient for metastatic and non-metastatic breast cancers, respectively); global cost saving is estimated to €29 millions. Regarding blood transfusion the cost saving is estimated to €1.6 millions. Impact of Ferinject on the decrease of ESA dosing in gastrointestinal cancer was evaluated on the same basis. The annual cost saving is estimated to €6.6 millions. Analysis showed that strategies including intravenous iron remained cost-effective even with wide variations in the assumptions. CONCLUSIONS: Compared with usual therapeutic strategies of anemia, the use of intravenous iron appears to be significantly cost saving in chemotherapy-induced anemia in breast cancers and gastrointestinal cancers.
PCN29 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) USING RITUXIMAB (R) WITH FLUDARABINE (F) AND CYCLOPHOSPHAMIDE (C): ASSESSING THE FINANCIAL IMPACT OF THE ROUTE OF ADMINISTRATION AT PRINCESS MARGARET HOSPITAL (PMH)
Douglas P 1 , Lee R 2 , Worthington K 1 , Mistry B 1 1 Hoffmann-La Roche Limited, Mississauga, ON, Canada, 2 University Health Network, Toronto, ON, Canada OBJECTIVES: The objective of this study was to determine, from the perspective of PMH, the financial impact of treating patients with CLL using R and intravenous FC (R-FC IV) versus R and orally administered FC (R-FC PO). METHODS: A cost analysis was performed from the perspective of PMH. All drug and administration costs were obtained from relevant sources in the province of Ontario and validated by PMH. Rituximab dosing was set at 375 mg/m 2 for cycle 1 (day 1) and 500 mg/m 2 of cycles 2-6 (day 1). Intravenous F and C were dosed at 25 mg/m 2 and 250 mg/m 2 , respectively, for 6 cycles (days 1-3). Oral dosing of these drugs was set at 40 mg/m 2 and 325 mg/m 2 , respectively. Drug utilization was estimated based on a body surface area of 1.8 m 2 . RESULTS: The cost of R-FC PO at PMH is $32,634 per patient (Drug cost: $29,292; Administration cost: $3,342), while the cost of R-FC IV is $33,400 per patient (Drug cost: $25,192; Administration cost: $8,208). Overall, utilization of R-FC PO is $766, or 2%, less costly than R-FC IV at PMH. Real-world conditions would impact the difference in price between these two options, as patients may tolerate more treatment cycles of one regimen compared to another. The cost of the PO and IV routes of administration may be viewed as functionally equivalent at PMH, making the decision to employ a specific route of administration one that should be based on non-financial criteria. These results should apply to all Canadian hospitals with drug and administration costs that are similar to those found at PMH. CONCLUSIONS: This analysis shows that R-FC PO is marginally less expensive than R-FC IV at PMH. Therefore, the choice of format should be made based on patients' individual needs.
PCN30 DOES A LACK OF HTA REVIEW LEAD TO HIGHER PRICES FOR HIV TREATMENTS? A COMPARISON WITH ONCOLOGY TREATMENTS
Nordyke R 1 , Imbeah-Ampiah R 2 , Ng-Haing J 2 , Oshinowo B 2 , Saraf S 2 1 PriceSpective LLC, El Segundo, CA, USA, 2 PriceSpective Ltd., London, UK OBJECTIVES: Therapies for HIV and cancer draw attention due to both high unmet need and high costs. In some cases, HIV treatments are approaching the prices of cancer treatments. However these disease states are often reviewed differently by payers and HTA agencies. NICE, for example, does not perform HTAs for HIV therapies while other European countries do. We examined the relative differences in prices between HIV and cancer therapies across several European countries to identify the potential impact of HTA reviews. METHODS: We included therapies approved for use 2004 -2010 and cancer (Alimta, Avastin, Erbitux, Sutent, Tyverb,Taxotere, Nexavar). Current yearly treatment prices (2010) were identified for all therapies for UK, FR, DE, IT, and ES. Price differentials between the UK and other countries were determined for each treatment. Mean country price differentials (UK reference) were compared. RESULTS: HIV therapies were on average 30% (median differential 29%) lower in price in the UK than other countries. Price differentials for HIV therapy ranged from Ϫ18% (higher price in UK) to 75% (less expensive in UK). Cancer therapy prices averaged 36% (median 36%) lower in UK than other countries. Price differentials for HIV therapy ranged from 6% to 80% (lower price in UK) with a median of 36%. The apparent discrepancy between mean country differentials was not present if the single HIV therapy was more expensive in the UK than other European countries (Norvir was excluded). CONCLUSIONS: Across 9 HIV therapies and 7 cancer treatments, all treatments were on average lower in price in the UK. However, the price differential was not substantially different across the 2 therapy areas. There is little evidence supporting an upward price pressure due to a lack of economic-driven HTA reviews of HIV products when compared to oncology therapies.
PCN31 DIRECT MEDICAL COSTS OF ELDERLY PATIENTS WITH STAGE III COLON CANCER DURING FIRST-LINE VERSUS SECOND-LINE CHEMOTHERAPY
Yang HK, Bikov K, Onukwugha E, Mullins CD University of Maryland School of Pharmacy, Baltimore, MD, USA OBJECTIVES: Economic analyses of stage III colon cancer (CC) treatments should account for multiple lines of chemotherapy, yet little is known about the cost variation between first-line (1stTx) and second-line chemotherapy (2ndTx). This study investigates the direct medical costs of 1stTx and 2ndTx among elderly American patients with stage III CC. METHODS: We included patients over 65 years and diagnosed with stage III CC from the 1997-2005 Surveillance, Epidemiology, and End Results (SEER)-Medicare database. 1stTx was defined as any use of 5-fluorouracil/leucovorin-only, oxaliplatin-based, or irinotecan-based chemotherapies; 2ndTx was the chemotherapy following the 1stTx after a therapy gap of at least 12 weeks or a switch in chemotherapy. 1stTx and 2ndTx were examined during the first 40 weeks following chemotherapy initiation. Cost data representing total Medicare reimbursements were used to calculate weekly costs for the first 26 weeks of each treatment. We further examined the cost difference between patients who started 2ndTx early (Յ26 weeks) and late (Ͼ26 weeks). RESULTS: Among 18,378 elderly patients with stage III CC, 57% received 1stTx (nϭ10,408). Among 1stTx users, 8% (nϭ870) went on to receive 2ndTx. Average weekly total medical costs for 1stTx varied between $647 and $1,493 (meanϮSDϭ$895Ϯ166) while these for 2ndTx were higher, ranging from $752 to $2,041 (meanϮSDϭ$1,046Ϯ286). Furthermore, average weekly total medical costs of 2ndTx in patients who started 2ndTx early ranged from $900 to $2,093 (meanϮSDϭ$1,251Ϯ318), reflecting higher costs than among late 2ndTx users, whose costs ranged from $767 to $1,483 (meanϮSDϭ$1,011Ϯ226). CONCLUSIONS: Average weekly total medical costs of stage III CC patients were higher for 2ndTx than 1stTx. Early 2ndTx initiators also had higher average weekly total medical costs than late 2ndTx users. Findings suggest that direct medical costs of stage III CC patients are lower when they are on first-line than second-line chemotherapy. 
PCN32
COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CHRONIC KIDNEY DISEASE AND CHEMOTHERAPY-INDUCED ANEMIA OUTPATIENTS
OBJECTIVES:
Red blood cell transfusion is the standard of care for many patients with myelodysplastic syndrome (MDS) in the US. Transfusions are economically burdensome due to the costs associated with the transfusions including iron chelation therapy (ICT). This study aimed to investigate potential cost savings associated with transfusion independence as a result of lenalidomide use. METHODS: A one-year simulation model was constructed to estimate the relevant costs of using lenalidomide compared to transfusions in the treatment of MDS patients with a 5qdeletion and transfusion-dependent anemia. A two arm model was constructed to simulate patients through the costs of lenalidomide vs. transfusions. Patients were assigned initial transfusion and ICT requirements, response status, risk of infection, death, progression to acute myeloid leukemia (AML), and iron overload complications (IOC) based on data from a clinical trial and existing literature. Patients who became transfusion independent were subject to lower risk of infection, death, progression to AML and elimination of ICT. Dosing frequency and modification of lenalidomide was simulated based on results of the MDS-003 clinical trial. Treatment guidelines also served as a basis of assumptions when required. Resource use and cost data (in 2010 US dollars) were obtained from US databases and available literature. RESULTS: In a scenario where it was assumed that patients became transfusion independent with lenalidomide use, a patient's cost was $119,186 inclusive of the cost of lenalidomide, whereas the costs for a transfusion dependent patient were $77,729. In this scenario, patients receiving lenalidomide experienced reduced infections, IOCs, progression to AML and ICT compared to patients treated with transfusions. CONCLUSIONS: In the US, treating MDS patients with transfusion-dependent anemia and a 5q-deletion with lenalidomide results in cost savings due to a reduction in costs from transfusion related complications. These savings serve to largely offset lenalidomide treatment costs.
PCN34
LONG-TERM DIRECT MEDICAL COSTS IN PATIENTS DIAGNOSED WITH FOLLICULAR LYMPHOMA WHO RECEIVE FRONTLINE CHEMOTHERAPY WITH VERSUS WITHOUT RITUXIMAB -A SEER MEDICARE ANALYSIS
